Kevin O'brien
About Kevin O'brien
Kevin O'Brien is a Senior Scientist at Inozyme Pharma, specializing in CRISPR-based gene editing and adenovirus production. He holds a BA in Biology and Biochemistry from the College of the Holy Cross and a PhD in Microbiology from the University of Georgia.
Work at Inozyme
Kevin O'Brien has been serving as a Senior Scientist at Inozyme Pharma since 2019. In this role, he focuses on advancing research initiatives within the organization. His position involves applying his expertise in molecular biology and gene editing techniques to contribute to the company's scientific objectives. O'Brien's work is integral to the development of innovative therapies and solutions in the pharmaceutical sector.
Education and Expertise
Kevin O'Brien earned a Bachelor of Arts in Biology and Biochemistry from the College of the Holy Cross, studying from 2008 to 2011. He then pursued a Doctor of Philosophy in Microbiology at The University of Georgia from 2011 to 2016. His academic background provides a solid foundation for his expertise in CRISPR-based gene editing techniques and adenovirus production, which are critical in molecular biology research.
Background
Before joining Inozyme Pharma, Kevin O'Brien worked as a PhD candidate at the University of Georgia from 2011 to 2016, where he developed his research skills. Following this, he completed a two-year postdoctoral fellowship at UMass Medical School in the Kobertz Laboratory from 2016 to 2018. His diverse experiences in academic research settings have shaped his scientific approach and collaborative mindset.
Achievements
Kevin O'Brien has demonstrated a commitment to mentoring the next generation of scientists, emphasizing the importance of guidance and support in scientific education. He actively engages in collaborative research projects, which highlight his belief in teamwork as a vital component of scientific discovery. His proficiency in fluorescent microscopy further enhances his contributions to understanding cellular processes.